Genentech provides support to help facilitate access to Genentech Oncology medicines for eligible patients. A list of Genentech Oncology medicines, indications, and program information is provided in the Table.
Genentech Oncology Access Solutions
The assistance provided by Genentech Oncology Access Solutions varies based on the patient’s prescribed medication and insurance status.
Genentech Oncology Co-pay Assistance Program
The copay program provides direct financial assistance to commercially insured patients to help with their copays, coinsurance, or other out-of-pocket costs. To be eligible for this program, patients must:
Be covered by commercial or private insurance
Be aged ≥18 years
Be receiving a Genentech Oncology product for an FDA-approved indication
Reside and receive treatment in the United States or US territories
Not be insured by state- or government-funded health plans, such as Medicare, Medicaid, Medigap, or TRICARE
Not be receiving assistance through the Genentech Patient Foundation or any other copay charitable organization.
Patients may pay as little as $5 for their prescribed Genentech Oncology product, with an annual benefit limit of $25,000 per product. Visit CopayAssistanceNow.com or call 855-692-6729 to learn more.
Genentech Patient Foundation
Eligible patients who meet specified criteria may qualify to receive their Genentech medication at no cost through the Genentech Patient Foundation. Patients may qualify if they:
Are uninsured or insured but without coverage for a Genentech medicine
Have a household adjusted gross income of $150,000 or less
Have insurance that covers Genentech medicines but have unaffordable out-of-pocket costs and have pursued other forms of financial assistance.
Click here to help your patient apply, or for more information.
Genentech Access Solutions staff can connect patients to independent copay assistance foundations. Drug-specific listings of foundations are available at Genentech-Access.com.
TABLE Genentech Oncology Drugs
Patient support programs
Actemra (tocilizumab) injection
Treatment of cytokine release syndrome induced by CAR T-cell therapy
Adjuvant treatment of HER2-positive breast cancer, in combination with chemotherapy, or alone after multiple anthracycline-based therapies; treatment of HER2-positive metastatic breast cancer, either first-line or after ≥1 chemotherapies for metastatic disease
Treatment of metastatic HER2-positive breast cancer; adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease after neoadjuvant taxane and trastuzumab-based therapy
Treatment of adults with CLL or SLL; treatment, in combination with azacitidine, or decitabine, or low-dose cytarabine, of newly diagnosed AML in patients aged ≥75 years, or those who have comorbidities that preclude use of intensive induction chemotherapy
AML indicates acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DLBCL, diffuse large B-cell lymphoma; NSCLC, non–small-cell lung cancer; SLL, small lymphocytic lymphoma.
Avastin (bevacizumab) Indications
First- or second-line treatment of metastatic CRC, in combination with 5-fluorouracil–based chemotherapy; second-line treatment of metastatic CRC, in combination with fluoropyrimidine/irinotecan- or fluoropyrimidine-oxaliplatin–based chemotherapy in patients whose disease progressed with a first-line regimen containing Avastin; first-line treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel; recurrent glioblastoma in adults; metastatic renal-cell carcinoma, in combination with interferon-alfa; persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan; treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, followed by Avastin monotherapy, or in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease after ≤2 chemotherapy regimens, or in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin monotherapy, for platinum-sensitive recurrent disease
Gavreto (pralsetinib) capsules Indications
Treatment of adult patients with metastatic RET fusion–positive NSCLC as detected by an FDA-approved test; treatment of adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy; treatment of adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
Gazyva (obinutuzumab) Indications
First-line treatment of CLL, in combination with chlorambucil; in combination with bendamustine followed by Gazyva monotherapy, in follicular lymphoma relapsed after, or refractory to, a rituximab-containing regimen; in combination with chemotherapy followed by Gazyva monotherapy in patients achieving at least a partial remission, for previously untreated stage II bulky, III, or IV follicular lymphoma
Herceptin (trastuzumab) Indications
Adjuvant treatment of HER2-positive breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or as part of a treatment regimen with docetaxel and carboplatin, or as a single agent following multimodality anthracycline-based therapy, based on an FDA-approved companion diagnostic for Herceptin; in combination with paclitaxel for first-line treatment of HER2-positive metastatic breast cancer, or as a single agent in patients who have received ≥1 chemotherapy regimens for metastatic disease, based on an FDA-approved companion diagnostic for Herceptin; in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease, based on an FDA-approved companion diagnostic for Herceptin
Perjeta (pertuzumab) Indications
In combination with trastuzumab and docetaxel, treatment of HER2-positive metastatic breast cancer in patients without prior anti-HER2 therapy or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, and the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Indications
Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer; adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence; treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease
Rituxan Hycela (rituximab and hyaluronidase human) injection Indications
Relapsed or refractory follicular lymphoma; first-line treatment of follicular lymphoma, in combination with chemotherapy, and as maintenance monotherapy in patients with complete or partial response to rituximab plus chemotherapy; as monotherapy for nonprogressing follicular lymphoma after first-line chemotherapy; untreated DLBCL, in combination with chemotherapy; CLL, in combination with fludarabine and cyclophosphamide
Tecentriq (atezolizumab) Indications
Treatment of locally advanced or metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy and whose tumors express PD-L1, as determined by an FDA-approved test, or for patients ineligible for platinum-based chemotherapy, regardless of PD-L1 status, or those whose disease progressed during or after platinum-based chemotherapy within 12 months of neoadjuvant or adjuvant chemotherapy; first-line treatment of adults with metastatic NSCLC and high PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations; first-line treatment, in combination with bevacizumab, paclitaxel, and carboplatin, or in combination with paclitaxel protein-bound and carboplatin, of adults with metastatic nonsquamous NSCLC and no EGFR or ALK mutations; treatment of adults with metastatic NSCLC whose disease progressed during or after platinum-containing chemotherapy, or in patients with EGFR or ALK mutations whose disease progressed while using FDA-approved therapy for NSCLC harboring these mutations; treatment, in combination with paclitaxel protein-bound, of adults with unresectable locally advanced or metastatic triple-negative breast cancer and PD-L1 expression, as determined by an FDA-approved test; first-line treatment, in combination with carboplatin and etoposide, of adults with extensive-stage small-cell lung cancer; treatment, in combination with bevacizumab, of patients with unresectable or metastatic hepatocellular carcinoma who have not received previous systemic therapy; treatment, in combination with cobimetinib and vemurafenib, of patients with unresectable or metastatic melanoma and BRAF V600 mutation
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?